RU2010119041A - Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи - Google Patents
Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи Download PDFInfo
- Publication number
- RU2010119041A RU2010119041A RU2010119041/15A RU2010119041A RU2010119041A RU 2010119041 A RU2010119041 A RU 2010119041A RU 2010119041/15 A RU2010119041/15 A RU 2010119041/15A RU 2010119041 A RU2010119041 A RU 2010119041A RU 2010119041 A RU2010119041 A RU 2010119041A
- Authority
- RU
- Russia
- Prior art keywords
- solid particle
- enteric coating
- pharmaceutical composition
- active agent
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
1. Способ лечения нарушения желудочно-кишечного тракта у пациента, нуждающегося в этом лечении, включающий стадии: ! введение указанному пациенту фармацевтической композиции, содержащей терапевтически эффективное количество лекарственной формы, включающей ингибитор протонного насоса, в котором указанную фармацевтическую композицию можно вводить пациенту независимо от приема пищи. ! 2. Способ лечения нарушения желудочно-кишечного тракта у пациента, нуждающегося в этом лечении, включающий стадии: ! введение указанному пациенту фармацевтической композиции, содержащей терапевтически эффективное количество: ! (a) первой твердой частицы, где указанная первая твердая частица содержит активный агент и первое энтеросолюбильное покрытие, причем первое энтеросолюбильное покрытие высвобождает активный агент из твердой частицы при pH от приблизительно 5,0 до приблизительно 5,5; и ! (b) второй твердой частицы, где указанная вторая твердая частица содержит активный агент и второе энтеросолюбильное покрытие, причем второе энтеросолюбильное покрытие высвобождает активный агент из твердой частицы при pH от приблизительно 6,2 до приблизительно 6,8; ! в котором первая твердая частица содержит от приблизительно 15 вес.% до приблизительно 50 вес.% фармацевтической композиции и вторая твердая частица содержит от приблизительно 50 вес.% до приблизительно 85 вес.% фармацевтической композиции; и ! дополнительно в котором указанную фармацевтическую композицию можно вводить пациенту независимо от приема пищи. ! 3. Способ по п.2, в котором активный агент в первой твердой частице представляет собой декслансопразол. ! 4. Способ по п.2, в котор�
Claims (18)
1. Способ лечения нарушения желудочно-кишечного тракта у пациента, нуждающегося в этом лечении, включающий стадии:
введение указанному пациенту фармацевтической композиции, содержащей терапевтически эффективное количество лекарственной формы, включающей ингибитор протонного насоса, в котором указанную фармацевтическую композицию можно вводить пациенту независимо от приема пищи.
2. Способ лечения нарушения желудочно-кишечного тракта у пациента, нуждающегося в этом лечении, включающий стадии:
введение указанному пациенту фармацевтической композиции, содержащей терапевтически эффективное количество:
(a) первой твердой частицы, где указанная первая твердая частица содержит активный агент и первое энтеросолюбильное покрытие, причем первое энтеросолюбильное покрытие высвобождает активный агент из твердой частицы при pH от приблизительно 5,0 до приблизительно 5,5; и
(b) второй твердой частицы, где указанная вторая твердая частица содержит активный агент и второе энтеросолюбильное покрытие, причем второе энтеросолюбильное покрытие высвобождает активный агент из твердой частицы при pH от приблизительно 6,2 до приблизительно 6,8;
в котором первая твердая частица содержит от приблизительно 15 вес.% до приблизительно 50 вес.% фармацевтической композиции и вторая твердая частица содержит от приблизительно 50 вес.% до приблизительно 85 вес.% фармацевтической композиции; и
дополнительно в котором указанную фармацевтическую композицию можно вводить пациенту независимо от приема пищи.
3. Способ по п.2, в котором активный агент в первой твердой частице представляет собой декслансопразол.
4. Способ по п.2, в котором активный агент во второй твердой частице представляет собой декслансопразол.
5. Способ по п.2, в котором активный агент в первой твердой частице и во второй твердой частице представляет собой декслансопразол.
6. Способ по п.2, в котором первое энтеросолюбильное покрытие имеет рН приблизительно 5,5.
7. Способ по п.6, в котором первое энтеросолюбильное покрытие содержит дисперсию сополимера метакриловой кислоты.
8. Способ по п.2, в котором второе энтеросолюбильное покрытие имеет рН приблизительно 6,75.
9. Способ по п.8, в котором второе энтеросолюбильное покрытие содержит смесь сополимера метакриловой кислоты типа B и сополимера метакриловой кислоты типа A в отношении 3:1.
10. Способ по п.2, в котором первая твердая частица содержит защитный слой между активным агентом и первым энтеросолюбильным покрытием.
11. Способ по п.2, в котором вторая твердая частица содержит защитный слой между активным агентом и вторым энтеросолюбильным покрытием.
12. Способ по п.10 или 11, в котором защитный слой представляет собой сахарозу, гипромеллозу, неэнтеросолюбильное покрытие или любую их комбинацию.
13. Способ по п.12, в котором неэнтеросолюбильное покрытие представляет собой гидроксипропилцеллюлозу.
14. Способ по п.2, в котором первая твердая частица содержит приблизительно 25% фармацевтической композиции, и вторая твердая частица содержит приблизительно 75% фармацевтической композиции.
15. Способ по п.2, в котором первая твердая частица представляет собой гранулу.
16. Способ по п.2, в котором вторая твердая частица представляет собой гранулу.
17. Способ по п.2, в котором фармацевтическая композиция представляет собой таблетку или капсулу.
18. Способ по п.2, в котором нарушение жедудочно-кишечного тракта представляет собой изжогу, воспалительную болезнь кишечника, болезнь Крона, синдром раздраженного кишечника, язвенный колит, пептическую язву, стрессовую язву, кровоточащую пептическую язву, дуоденальную язву, инфекционный энтерит, колит, дивертикулит, повышенную кислотность желудка, диспепсию, гастропарез, синдром Золлингера-Эллисона, гастроэзофагеальную рефлюксную болезнь, заболевание, вызванное Helicobacter pylori, синдром укороченной кишки, гиперсекреторные состояния, связанные с системным мастоцитозом или базофильным лейкозом, или гипергистаминемией, или комбинации любых из вышеупомянутых нарушений.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99875407P | 2007-10-12 | 2007-10-12 | |
US60/998,754 | 2007-10-12 | ||
US12/249,258 US8173158B2 (en) | 2007-10-12 | 2008-10-10 | Methods of treating gastrointestinal disorders independent of the intake of food |
US12/249,258 | 2008-10-10 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013106514/15A Division RU2013106514A (ru) | 2007-10-12 | 2008-10-10 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
RU2014112070/15A Division RU2563993C1 (ru) | 2007-10-12 | 2014-03-28 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2010119041A true RU2010119041A (ru) | 2011-11-20 |
Family
ID=40534459
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010119041/15A RU2010119041A (ru) | 2007-10-12 | 2008-10-10 | Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи |
RU2013106514/15A RU2013106514A (ru) | 2007-10-12 | 2008-10-10 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
RU2014112070/15A RU2563993C1 (ru) | 2007-10-12 | 2014-03-28 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013106514/15A RU2013106514A (ru) | 2007-10-12 | 2008-10-10 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
RU2014112070/15A RU2563993C1 (ru) | 2007-10-12 | 2014-03-28 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
Country Status (16)
Country | Link |
---|---|
US (1) | US8173158B2 (ru) |
EP (1) | EP2203068A4 (ru) |
JP (2) | JP5629581B2 (ru) |
KR (3) | KR20170097787A (ru) |
CN (2) | CN104069088A (ru) |
AU (1) | AU2008310735B2 (ru) |
BR (1) | BRPI0818286A2 (ru) |
CA (1) | CA2702356C (ru) |
CO (1) | CO6260019A2 (ru) |
HK (1) | HK1202441A1 (ru) |
IL (1) | IL204886B (ru) |
MX (1) | MX2010003917A (ru) |
MY (1) | MY153062A (ru) |
RU (3) | RU2010119041A (ru) |
SG (1) | SG185296A1 (ru) |
WO (1) | WO2009049160A1 (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1768668A2 (en) | 2004-06-16 | 2007-04-04 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
KR20170097787A (ko) * | 2007-10-12 | 2017-08-28 | 다케다 파마슈티칼스 유에스에이, 인코포레이티드 | 음식 섭취와 관계없이 위장 장애를 치료하는 방법 |
CN105343885A (zh) * | 2009-11-20 | 2016-02-24 | 汉达医药有限责任公司 | 右兰索拉唑的口服配方 |
CN102120030B (zh) * | 2010-01-08 | 2013-07-10 | 丽珠医药集团股份有限公司 | 一种艾普拉唑化学结构的药物及其用途 |
US8563035B2 (en) * | 2010-05-05 | 2013-10-22 | Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi | Oral tablet compositions of dexlansoprazole |
EP2384745A3 (en) | 2010-05-05 | 2012-01-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Modified release pharmaceutical compositions of dexlansoprazole |
EP2384746A3 (en) * | 2010-05-05 | 2012-03-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Dual release oral tablet compositions of dexlansoprazole |
US20120164233A1 (en) | 2010-07-30 | 2012-06-28 | Ranbaxy Laboratories Limited | Pulsatile release pharmaceutical formulation of dexlansoprazole |
US9233103B2 (en) * | 2011-03-25 | 2016-01-12 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
WO2013111149A1 (en) * | 2011-12-21 | 2013-08-01 | Hetero Research Foundation | Controlled release solid oral compositions of dexlansoprazole |
CN102600109B (zh) * | 2012-04-13 | 2014-09-17 | 乐普药业股份有限公司 | 一种右兰索拉唑迟释胶囊及其制备方法 |
CN105769824A (zh) * | 2014-12-16 | 2016-07-20 | 四川海思科制药有限公司 | 一种兰索拉唑缓释胶囊及其制备方法 |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
CN104940169B (zh) * | 2015-06-26 | 2017-10-10 | 山东省药学科学院 | 一种右兰索拉唑缓释胶囊及其制备方法 |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
BE1025137B1 (nl) * | 2017-12-22 | 2018-11-09 | Nutri-Ad International Nv | Diervoeder materiaal |
WO2021002645A1 (ko) * | 2019-07-01 | 2021-01-07 | 연세대학교 산학협력단 | 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물 |
CN112168965A (zh) * | 2019-07-05 | 2021-01-05 | 中国科学院生物物理研究所 | SRCAP ATPase激动剂在肠道干细胞自我更新受抑介导的疾病治疗中的应用 |
EP4153145A4 (en) * | 2020-05-18 | 2024-05-29 | Board of Regents, The University of Texas System | GRANULES FOR 3D PRINTING TECHNOLOGY |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2996431A (en) | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
US2957880A (en) | 1953-12-23 | 1960-10-25 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
US4182756A (en) | 1977-11-21 | 1980-01-08 | Abbott Laboratories | High calorie solutions of low molecular weight glucose polymer mixtures useful for intravenous administration |
US4464170A (en) | 1982-09-29 | 1984-08-07 | Miles Laboratories, Inc. | Blood glucose control apparatus and method |
US4773907A (en) | 1982-12-20 | 1988-09-27 | Alza Corporation | Primary delivery system comprising secondary dosage form |
DK58983D0 (da) | 1983-02-11 | 1983-02-11 | Leo Pharm Prod Ltd | Farmaceutisk praeparat |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4777049A (en) | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
US5011692A (en) | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US5433959A (en) | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
US4904476A (en) | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
IE58401B1 (en) | 1986-06-20 | 1993-09-08 | Elan Corp Plc | Controlled absorption pharmaceutical composition |
US5330982A (en) | 1986-12-17 | 1994-07-19 | Glaxo Group Limited | Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith |
IT1201136B (it) | 1987-01-13 | 1989-01-27 | Resa Farma | Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
DK171989B1 (da) | 1987-08-04 | 1997-09-08 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler |
JP2733849B2 (ja) | 1987-10-12 | 1998-03-30 | ボロディー,ソーマス・ユリウス | 胃腸障害治療のための改良された方法 |
DE3822095A1 (de) | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
FR2655266B1 (fr) | 1989-12-05 | 1992-04-03 | Smith Kline French Lab | Compositions pharmaceutiques a base de cimetidine. |
US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
US5264223A (en) | 1990-03-29 | 1993-11-23 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
IT1246382B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
DE4035455A1 (de) | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | Enantiomerentrennung |
GEP19971086B (en) * | 1991-02-22 | 1997-12-02 | Tillotts Pharma Ag | Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine |
JP2552937Y2 (ja) | 1991-05-18 | 1997-11-05 | 株式会社堀場製作所 | 磁気式酸素分析装置 |
US5178867A (en) | 1991-08-19 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug in short-time period |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5262173A (en) | 1992-03-02 | 1993-11-16 | American Cyanamid Company | Pulsatile once-a-day delivery systems for minocycline |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
JP3277342B2 (ja) | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
US5431917A (en) | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
US5260069A (en) * | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5656290A (en) | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
ATE245814T1 (de) | 1993-11-02 | 2003-08-15 | U D Testing Inc | Verffahren zum überwachen der befolgung einer vorgeschriebenen medikation durch einen patienten |
SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
MX9600857A (es) | 1994-07-08 | 1997-06-28 | Astra Ab | Forma de dosificacion i en tabletas, con unidades multiples. |
SE504459C2 (sv) | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
PE32296A1 (es) | 1994-07-28 | 1996-08-07 | Hoffmann La Roche | Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables |
US5516351A (en) | 1994-08-05 | 1996-05-14 | Recycled Glass Products, Inc. | Foamed glass manufacture |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
US5807577A (en) | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
US6096339A (en) | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
US5817388A (en) | 1996-11-08 | 1998-10-06 | Carl M. Rodia & Associates | Multi-component dye compositions for optical recording media |
EP0951278A2 (en) | 1997-01-03 | 1999-10-27 | ELAN CORPORATION, Plc | Sustained release cisapride mini-tablet formulation |
US6162463A (en) | 1997-05-01 | 2000-12-19 | Dov Pharmaceutical Inc | Extended release formulation of diltiazem hydrochloride |
SE510650C2 (sv) | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
US5889051A (en) | 1997-07-15 | 1999-03-30 | Development Center For Biotechnology | Stabilization of prostaglandin drug |
DE19755682A1 (de) | 1997-12-15 | 1999-06-17 | Knoll Ag | Verfahren zur Ermittlung eines Dosierungschemas für Thrombininhibitoren |
SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
SE9704869D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
EP1056456A4 (en) | 1998-01-30 | 2006-10-25 | Sepracor Inc | R-LANSOPRAZOL COMPOSITIONS AND TREATMENTS THEREFOR |
JP4127740B2 (ja) | 1998-04-20 | 2008-07-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定化したベンズイミダゾール系化合物含有組成物 |
DE19820529A1 (de) | 1998-05-08 | 1999-11-11 | Lohmann Therapie Syst Lts | Wirkstoff enthaltende orale und mucosale Zubereitung mit steuerbarer Wirkstofffreisetzung und ihre Verwendung |
EP1121103B1 (en) | 1998-05-18 | 2006-12-20 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets comprising a benzimidazole |
ZA9810765B (en) | 1998-05-28 | 1999-08-06 | Ranbaxy Lab Ltd | Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole. |
JP3449253B2 (ja) | 1998-10-29 | 2003-09-22 | シオノギクオリカプス株式会社 | 硬質カプセルの製造方法 |
TWI289557B (en) | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
JP2001122769A (ja) | 1999-10-22 | 2001-05-08 | Lion Corp | 固形製剤及び固形製剤の崩壊・溶出性改善方法 |
DE60124692T2 (de) | 2000-04-28 | 2007-09-13 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten |
ES2521690T3 (es) | 2000-05-15 | 2014-11-13 | Takeda Pharmaceutical Company Limited | Procedimiento para producir un cristal de (R)-2-[[[3-metil-4-(2,2,2-trifluoroetoxi)-2-piridil]metil]sulfinil]-bencimidazol |
IT1318625B1 (it) | 2000-07-14 | 2003-08-27 | Roberto Valducci | Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. |
US7271182B2 (en) | 2000-08-04 | 2007-09-18 | Takeda Pharmaceutical Company Limited | Salts of benzimidazole compound and use thereof |
PT1337525E (pt) | 2000-12-01 | 2011-09-01 | Takeda Pharmaceutical | Processo para a cristalização de (r)- ou (s)-lansoprazole |
PT1341528E (pt) | 2000-12-07 | 2012-03-20 | Nycomed Gmbh | Comprimido de desintegração rápida compreendendo um ingrediente activo lábil a ácido |
PL201766B1 (pl) * | 2001-01-31 | 2009-05-29 | Roehm Gmbh | Wielocząsteczkowa postać leku zawierająca przynajmniej dwa typy granulek powlekanych w odmienny sposób oraz jej zastosowanie |
CN100562317C (zh) | 2001-10-17 | 2009-11-25 | 武田药品工业株式会社 | 含大量酸不稳定药物的颗粒 |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
EP2596792A1 (en) * | 2002-10-16 | 2013-05-29 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
ZA200502318B (en) * | 2002-10-16 | 2006-11-29 | Takeda Pharmaceutical | Controlled release preparation |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
JP4493970B2 (ja) * | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
US20040146558A1 (en) | 2003-01-28 | 2004-07-29 | Kyowa Pharmaceutical Co., Ltd. | Oral enteric-coated preparation |
JP4578124B2 (ja) * | 2003-03-12 | 2010-11-10 | 武田薬品工業株式会社 | 高濃度に活性成分を球形核に付着させた医薬組成物 |
CA2518780C (en) * | 2003-03-12 | 2014-05-13 | Takeda Pharmaceutical Company Limited | Drug composition having active ingredient adhered at high concentration to spherical core |
US8980322B2 (en) | 2003-03-17 | 2015-03-17 | Takeda Pharmaceutical Company Limited | Controlled release composition |
CA2557634A1 (en) * | 2004-03-04 | 2005-09-15 | Takeda Pharmaceutical Company Limited | Stable capsule preparation |
US20050226929A1 (en) * | 2004-04-12 | 2005-10-13 | Jianbo Xie | Controlled release opioid analgesic formulation |
EP1768668A2 (en) | 2004-06-16 | 2007-04-04 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
EP1621187A1 (en) * | 2004-07-26 | 2006-02-01 | AstraZeneca AB | Pharmaceutical multiparticulate tablet formulations and process for their preparation |
US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
FR2878161B1 (fr) | 2004-11-23 | 2008-10-31 | Flamel Technologies Sa | Forme medicamenteuse orale, solide et concue pour eviter le mesusage |
US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
FR2885526B1 (fr) | 2005-05-13 | 2007-07-27 | Flamel Technologies Sa | Medicament oral a base d'inhibiteur de pompe a protons |
DE102005024614A1 (de) | 2005-05-25 | 2006-11-30 | Röhm Gmbh | Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug |
DE102005032806A1 (de) | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
US20070026071A1 (en) * | 2005-07-28 | 2007-02-01 | Qpharma, Llc | Magnesium salt proton pump inhibitor dosage forms |
FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
KR20170097787A (ko) * | 2007-10-12 | 2017-08-28 | 다케다 파마슈티칼스 유에스에이, 인코포레이티드 | 음식 섭취와 관계없이 위장 장애를 치료하는 방법 |
US20090263475A1 (en) * | 2008-04-21 | 2009-10-22 | Nagaraju Manne | Dexlansoprazole compositions |
UA37196U (en) * | 2008-04-23 | 2008-11-25 | Национальный Университет Пищевых Технологий | Heat pump |
US20110189271A1 (en) * | 2010-02-02 | 2011-08-04 | Vishal Lad | Pharmaceutical formulations of acid-labile drugs |
EP2544667B1 (en) * | 2010-03-09 | 2018-11-14 | Alkermes Pharma Ireland Limited | Alcohol resistant enteric pharmaceutical compositions |
EP2384746A3 (en) * | 2010-05-05 | 2012-03-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Dual release oral tablet compositions of dexlansoprazole |
US8563035B2 (en) * | 2010-05-05 | 2013-10-22 | Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi | Oral tablet compositions of dexlansoprazole |
EP2384745A3 (en) * | 2010-05-05 | 2012-01-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Modified release pharmaceutical compositions of dexlansoprazole |
-
2008
- 2008-10-10 KR KR1020177022749A patent/KR20170097787A/ko not_active Application Discontinuation
- 2008-10-10 KR KR1020157013260A patent/KR20150084013A/ko active Application Filing
- 2008-10-10 CN CN201410289597.6A patent/CN104069088A/zh active Pending
- 2008-10-10 MY MYPI20101591 patent/MY153062A/en unknown
- 2008-10-10 RU RU2010119041/15A patent/RU2010119041A/ru not_active Application Discontinuation
- 2008-10-10 EP EP08837108A patent/EP2203068A4/en not_active Ceased
- 2008-10-10 US US12/249,258 patent/US8173158B2/en active Active
- 2008-10-10 JP JP2010529082A patent/JP5629581B2/ja active Active
- 2008-10-10 KR KR1020107010478A patent/KR20100116165A/ko active Search and Examination
- 2008-10-10 BR BRPI0818286-8A patent/BRPI0818286A2/pt not_active Application Discontinuation
- 2008-10-10 CN CN2008801191827A patent/CN102014638A/zh active Pending
- 2008-10-10 CA CA2702356A patent/CA2702356C/en active Active
- 2008-10-10 WO PCT/US2008/079520 patent/WO2009049160A1/en active Application Filing
- 2008-10-10 AU AU2008310735A patent/AU2008310735B2/en active Active
- 2008-10-10 RU RU2013106514/15A patent/RU2013106514A/ru not_active Application Discontinuation
- 2008-10-10 MX MX2010003917A patent/MX2010003917A/es active IP Right Grant
- 2008-10-10 SG SG2012075891A patent/SG185296A1/en unknown
-
2010
- 2010-04-06 IL IL204886A patent/IL204886B/en active IP Right Grant
- 2010-04-12 CO CO10041742A patent/CO6260019A2/es not_active Application Discontinuation
-
2013
- 2013-08-19 JP JP2013169403A patent/JP2014012692A/ja active Pending
-
2014
- 2014-03-28 RU RU2014112070/15A patent/RU2563993C1/ru active
-
2015
- 2015-03-27 HK HK15103105.9A patent/HK1202441A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2203068A4 (en) | 2012-08-22 |
IL204886B (en) | 2018-02-28 |
HK1202441A1 (en) | 2015-10-02 |
JP5629581B2 (ja) | 2014-11-19 |
JP2014012692A (ja) | 2014-01-23 |
WO2009049160A1 (en) | 2009-04-16 |
MY153062A (en) | 2014-12-31 |
AU2008310735A1 (en) | 2009-04-16 |
US8173158B2 (en) | 2012-05-08 |
JP2011500595A (ja) | 2011-01-06 |
KR20100116165A (ko) | 2010-10-29 |
AU2008310735B2 (en) | 2013-09-12 |
BRPI0818286A2 (pt) | 2020-08-11 |
EP2203068A1 (en) | 2010-07-07 |
CO6260019A2 (es) | 2011-03-22 |
IL204886A0 (en) | 2010-11-30 |
CA2702356C (en) | 2014-02-11 |
RU2563993C1 (ru) | 2015-09-27 |
KR20170097787A (ko) | 2017-08-28 |
RU2013106514A (ru) | 2015-03-10 |
MX2010003917A (es) | 2012-09-28 |
US20090098199A1 (en) | 2009-04-16 |
CN104069088A (zh) | 2014-10-01 |
SG185296A1 (en) | 2012-11-29 |
KR20150084013A (ko) | 2015-07-21 |
CA2702356A1 (en) | 2009-04-16 |
CN102014638A (zh) | 2011-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010119041A (ru) | Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи | |
JP2011500595A5 (ru) | ||
Lee et al. | Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis | |
Malfertheiner et al. | Peptic ulcer disease | |
Maradey-Romero et al. | New and future drug development for gastroesophageal reflux disease | |
Wolfe et al. | Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome | |
Wallace et al. | Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease | |
Wang et al. | Current pharmacological management of gastroesophageal reflux disease | |
WO2009017716A3 (en) | Pulsatile gastric retentive dosage forms | |
Martindale | Contemporary strategies for the prevention of stress-related mucosal bleeding | |
Castell et al. | Comparison of the effects of immediate‐release omeprazole powder for oral suspension and pantoprazole delayed‐release tablets on nocturnal acid breakthrough in patients with symptomatic gastro‐oesophageal reflux disease | |
JP2008534438A5 (ru) | ||
TW200509923A (en) | A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid | |
RU2013141534A (ru) | Составы l-ментола, состоящие из множества частиц, и связанные с ними способы | |
CA2318008A1 (en) | Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound | |
CA2605839A1 (en) | Stabilized composition of a proton pump inhibitor | |
Mössner et al. | Developments in the inhibition of gastric acid secretion | |
Wong et al. | Potassium-competitive acid blockers: present and potential utility in the armamentarium for acid peptic disorders | |
CA2566655A1 (en) | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them | |
Li et al. | The influence of different proton pump inhibitors and potassium‐competitive acid blockers on indomethacin‐induced small intestinal injury | |
Murakami et al. | Tu1056 a phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy with TAK-438, amoxicillin, and metronidazole as second Line eradication of H. pylori | |
Metz et al. | Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis | |
US20060235053A1 (en) | Agents for the treatment of lower abdominal disorders | |
Inamori et al. | Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use? | |
CA2648538A1 (en) | Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20131028 |